Table 1

Patient characteristics and C225 doses

Acc no.C225 dose (mg/m2; loading/weekly)Age (yr)/SexPrimary siteRecurrent sitePrevious therapy
1100/100630/FBase of tongueDermalSa + RT
2100/10036/MOral tongueLocoregionalS + RT + gene therapy
3100/10063/MAlveolar ridgeLocoregionalS + RT
4100/10072/MTonsilDermalS + RT
5100/10046/FSoft palateLocoregionalS + RT + 5-fluorouracil + cisplatin; IFN-α + 13-cRA
6500/25074/MBase of tongueDermalS + RT; paclitaxel + gemcitabine
7500/25050/MBase of tongueDermalS + RT
8500/25055/FLarynxDermalS + RT; 5-fluorouracil + cisplatin
10500/25078/FMucosal lipLocoregionalS + RT
9400/25055/MHypopharynxDermalS + RT
11400/25068/MRetromolar trigoneDistantS + bryostatin
12400/25039/FOral tongueLocoregionalS + RT; 5-fluorouracil + cisplatin + paclitaxel
  • a S, surgery; RT, radiation therapy; 13-cRA, 13-cis-retinoic acid.